Cargando…

Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells

BACKGROUND: Developing novel strategies against treatment-resistant triple negative breast cancer (TNBC) cells remains a significant challenge. The ErbB family, including epidermal growth factor receptor (EGFR), plays key roles in metastasis, tumorigenesis, cell proliferation, and drug resistance. R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanei, Tomonori, Choi, Dong Soon, Rodriguez, Angel A., Liang, Diana Hwang, Dobrolecki, Lacey, Ghosh, Madhumita, Landis, Melissa D., Chang, Jenny C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711100/ https://www.ncbi.nlm.nih.gov/pubmed/26757880 http://dx.doi.org/10.1186/s13058-015-0662-4

Ejemplares similares

5-FU and ixabepilone modify the microRNA expression profiles in MDA-MB-453 triple-negative breast cancer cells
por: YAO, YONGSHAN, et al.
Publicado: (2014)

Profile and potential of ixabepilone in the treatment of pancreatic cancer
por: Smaglo, Brandon G, et al.
Publicado: (2014)

Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients
por: Ebenezer, Gigi J, et al.
Publicado: (2014)

Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer
por: Cobham, Marta Vallee, et al.
Publicado: (2009)

Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
por: Cristofanilli, Massimo
Publicado: (2012)

Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer
por: Rak Tkaczuk, Katherine H.
Publicado: (2011)

Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone
por: Rivera, Edgardo, et al.
Publicado: (2010)

Management of advanced breast cancer with the epothilone B analog, ixabepilone
por: Gradishar, William
Publicado: (2009)

Ixabepilone: Overview of Effectiveness, Safety, and Tolerability in Metastatic Breast Cancer
por: Ibrahim, Nuhad K.
Publicado: (2021)

Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer
por: Egerton, Nancy
Publicado: (2010)

Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
por: Puhalla, Shannon, et al.
Publicado: (2008)

Ixabepilone development across the breast cancer continuum: a paradigm shift
por: Ibrahim, Nuhad K
Publicado: (2010)

Icaritin enhances the efficacy of cetuximab against triple-negative breast cancer cells
por: Yin, Li, et al.
Publicado: (2020)

Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer
por: Granados-Principal, Sergio, et al.
Publicado: (2015)

Immunologically “cold” triple negative breast cancers engraft at a higher rate in patient derived xenografts
por: Petrosyan, Varduhi, et al.
Publicado: (2022)

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry
por: Beumer, J. H., et al.
Publicado: (2007)

Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials
por: Vahdat, Linda T., et al.
Publicado: (2012)

HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway
por: Liu, Yi, et al.
Publicado: (2017)

Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer
por: Juliá, Estefanía Paula, et al.
Publicado: (2020)

Conjugation of Cetuximab – Puromycin and Its Target-Specific Effect on Triple Negative Breast Cancer Cell Lines
por: Puspitasari, Diah, et al.
Publicado: (2022)

The nature of triple-negative breast cancer classification and antitumoral strategies
por: Kim, Songmi, et al.
Publicado: (2020)

A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma
por: Ott, Patrick A., et al.
Publicado: (2010)

Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer
por: McKnight, Brooke N., et al.
Publicado: (2020)

Does conjugation strategy matter? Cetuximab-conjugated gold nanocages for targeting triple-negative breast cancer cells
por: Avvakumova, S., et al.
Publicado: (2019)

Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial
por: Fountzilas, George, et al.
Publicado: (2013)

Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple negative breast and ovarian carcinomas
por: Menghi, Francesca, et al.
Publicado: (2022)

A Phase II Multi‐Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma
por: Burotto, Mauricio, et al.
Publicado: (2017)

The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells
por: Tam, Stanton, et al.
Publicado: (2022)

Budget Impact Analysis of Ixabepilone Used According to FDA Approved Labeling in Treatment-Resistant Metastatic Breast Cancer
por: Ho, Joanne, et al.
Publicado: (2009)

Antitumor Activity of Noscapine in Combination with Doxorubicin in Triple Negative Breast Cancer
por: Chougule, Mahavir B., et al.
Publicado: (2011)

Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells
por: FUKUDA, KAZUMASA, et al.
Publicado: (2011)

A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy
por: Kim, Yeul Hong, et al.
Publicado: (2012)

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer
por: Owusu-Brackett, Nicci, et al.
Publicado: (2019)

Antitumor activity of new chemical compounds in triple negative mammary adenocarcinoma models
por: Giolito, María V, et al.
Publicado: (2020)

ELK3 modulates the antitumor efficacy of natural killer cells against triple negative breast cancer by regulating mitochondrial dynamics
por: Park, Joo Dong, et al.
Publicado: (2022)

Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells
por: Napolitano, Stefania, et al.
Publicado: (2017)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Antitumoral and antimetastatic activity of Maitake D-Fraction in triple-negative breast cancer cells
por: Alonso, Eliana Noelia, et al.
Publicado: (2018)

Fabrication of Ginsenoside-Based Nanodrugs for Enhanced Antitumor Efficacy on Triple-Negative Breast Cancer
por: Zuo, Shuting, et al.
Publicado: (2022)

Nicotinic receptors modulate antitumor therapy response in triple negative breast cancer cells
por: Español, Alejandro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qftm75g2a60p4tvbi0cmepoiu3